

DRUG DESIGN

Edited by E. J. Ariëns

VOLUME V






DRUG DESIGN


Edited by E. J. Ariëns

DEPARTMENT OF PHARMACOLOGY
UNIVERSITY OF NIJMEGEN
NIJMEGEN, THE NETHERLANDS

VOLUME V



ACADEMIC PRESS New York San Francisco London 1975
A Subsidiary of Harcourt Brace Jovanovich, Publishers



DRUG DESIGN

COPYRIGHT © 1975, BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003

VOLUME V

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1

Library of Congress Cataloging in Publication Data
Main entry under title:

Drug design.

(Medicinal chemistry: a series of monographs,
v. 11)

Includes bibliographies.

1. Pharmacology—Collected works. 2. Chemistry,
Medical and pharmaceutical—Collected works.
- I. Ariens, Everhardius Jacobus, ed. II. Series.
[DNLM: 1. Chemistry, Pharmaceutical. 2. Drug
compounding. 3. Pharmacology. W1ME64 v. 11]
RM300.D74 615'.1 72-127678
ISBN 0-12-060305-5 (v. 5)



PRINTED IN THE UNITED STATES OF AMERICA

JOHN G. TORRES (1), Chemical Research Department, Schering Corporation, Bloomfield, New Jersey
WILLIAM C. WERKHEISER* (169), Department of Experimental Therapeutics, and James T. Grace, Jr. Cancer Drug Center, New York State Department of Health, Roswell Park Memorial Institute, Buffalo, New York

* Deceased.

List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

PETER H. DOUKAS (133), Department of Biosciences, The School of Pharmacy, Temple University, Philadelphia, Pennsylvania

GERALD B. GRINDEY (169), Department of Experimental Therapeutics and James T. Grace, Jr. Cancer Drug Center, New York State Department of Health, Roswell Park Memorial Institute, Buffalo, New York

JOYCE J. KAUFMAN (251), Department of Chemistry, The Johns Hopkins University, and Division of Anesthesiology, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland

WALTER S. KOSKI (251), Department of Chemistry, The Johns Hopkins University, and Division of Anesthesiology, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland

ERIC J. LIEN (81), School of Pharmacy, University of Southern California, Los Angeles, California

R. N. LINDQUIST (23), Department of Chemistry, San Francisco State University, San Francisco, California

YVONNE C. MARTIN (1), Abbott Laboratories, Abbott Park, North Chicago, Illinois

RICHARD G. MORAN (169), Department of Experimental Therapeutics and James T. Grace, Jr. Cancer Drug Center, New York State Department of Health, Roswell Park Memorial Institute, Buffalo, New York

JOHN G. TOPLISS (1), Chemical Research Department, Schering Corporation, Bloomfield, New Jersey

WILLIAM C. WERKHEISER* (169), Department of Experimental Therapeutics, and James T. Grace, Jr. Cancer Drug Center, New York State Department of Health, Roswell Park Memorial Institute, Buffalo, New York

* Deceased.

List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- PETER H. DOKAS (133), Department of Biosciences, The School of Pharmacy, Temple University, Philadelphia, Pennsylvania
- GERALD B. GRINDY (169), Department of Experimental Therapeutics and James T. Grace, Jr. Cancer Drug Center, New York State Department of Health, Roswell Park Memorial Institute, Buffalo, New York
- JOYCE J. KAUFMAN (251), Department of Chemistry, The Johns Hopkins University, and Division of Anesthesiology, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- WALTER S. KOSKI (251), Department of Chemistry, The Johns Hopkins University, and Division of Anesthesiology, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- ERIC J. LIEN (81), School of Pharmacy, University of Southern California, Los Angeles, California
- R. N. LINDQUIST (23), Department of Chemistry, San Francisco State University, San Francisco, California
- YVONNE C. MARTIN (1), Abbot Laboratories, Abbott Park, North Chicago, Illinois
- RICHARD G. MORAN (169), Department of Experimental Therapeutics and James T. Grace, Jr. Cancer Drug Center, New York State Department of Health, Roswell Park Memorial Institute, Buffalo, New York

Preface

Rapid progress in the field of drug design, especially in the physicochemical approach to the relationship of structure and mechanism of action and the applicability of the insight gained to drug design, makes a thorough review of this field a necessity for scientists involved in drug development.

This volume offers the reader a number of chapters dealing with recent, fundamental approaches to the development of bioactive compounds, specifically, the design of enzyme inhibitors based on the development of transition state analogs, the rationale for the combination of enzyme inhibitors (anti-metabolites), and the physicochemical factors essential for drug distribution in the organ, including absorption and excretion. The chapter on operational schemes for analog synthesis, an approach ready for immediate use, is of particular interest. Chapters on the role of charge-transfer processes in the action of bioactive compounds and on physicochemical, quantum chemical, and related theoretical approaches to the understanding of compounds with action on the central nervous system open new perspectives for the future.

E. J. ARIËNS

Contents of Other Volumes

VOLUME I

A General Introduction to the Field of Drug Design

E. J. Ariëns

Quantitative Structure-Activity Relationships in Drug Design

Corwin Hansch

Physicochemical Approaches to the Rational Development of New Drugs

J. K. Seydel

A Molecular Orbital Approach to Quantitative Drug Design

A. J. Wohl

Electronic Aspects of Drug Action

Roger L. Schnaare

The Role of Biopharmaceutics in the Design of Drug Products

John G. Wagner

Significance of Pharmacokinetics for Drug Design and the Planning of Dosage Regimens

J. M. van Rossum

Author Index—Subject Index

VOLUME II

Modulation of Pharmacokinetics by Molecular Manipulation

E. J. Ariëns

Factors in the Design of Reversible and Irreversible Enzyme Inhibitors

Howard J. Schaeffer

The Design of Organophosphate and Carbamate Inhibitors of Cholinesterases

R. D. O'Brien

The Design of Reactivators for Irreversibly Blocked Acetylcholinesterase

I. B. Wilson and Harry C. Froede

Inhibition of Protein Biosynthesis: Its Significance in Drug Design

Arthur P. Grollman

Enzymes and Their Synthesis as a Target for Antibiotic Action

M. H. Richmond

The Rational Design of Antiviral Agents

Arthur P. Grollman and Susan B. Horwitz

Design of Penicillins

A. E. Bird and J. H. C. Naylor

The Design of Peptide Hormone Analogs

J. Rudinger

Recent Advances in the Design of Diuretics

George deStevens

Design of Biologically Active Steroids

G. A. Overbeek, J. van der Vies, and J. de Visser

Rational Elements in the Development of Superior Neuromuscular Blocking

Agents

M. Martin-Smith

The Design of Tumor-Inhibitory Alkylating Drugs

J. A. Stock

Author Index—Subject Index

VOLUME III

Microbial Conversion as a Tool in the Preparation of Drugs

R. Beukers, A. F. Marx, and M. H. J. Zuidweg

The Use of Linear Free Energy Parameters and Other Experimental Constants in Structure-Activity Studies

A. Verloop

Anticoagulants Structurally and Functionally Related to Vitamin K

*T. Kralt and V. Claassen*Design of β -Blocking Drugs*A. M. Barrett*

The Design of Biologically Active Acridines

Adrien Albert

The Design of Local Anesthetics

J. Büchi and X. Perlia

Design of Insect Chemosterilants

Ralph B. Turner

Molecular Approach for Designing Inhibitors to Enzymes Involved in Blood Clotting

L. Lorand and J. G. L. Nilsson

Author Index—Subject Index

VOLUME IV

Biopharmaceutics as a Basis for the Design of Drug Products

Leslie Z. Benet

Peroral Solid Dosage Forms with Prolonged Action

W. A. Ritschel

Parenteral Dosage Forms with Prolonged Action

W. A. Ritschel

Design of Topical Drug Products: Pharmaceuticals

Martin Katz

Design of Topical Drug Products: Biopharmaceutics

Boyd J. Poulsen

The Design of Sunscreen Preparations

Goswin W. van Ham and Wolfgang P. Herzog

Litholytic Agents: Preventive and Curative Drugs for Nephrolithiasis

George Kallistratos

The Design of Biologically Active Nucleosides

Alexander Bloch

The Design of Insecticidal Chlorohydrocarbon Derivatives

G. T. Brooks

Author Index—Subject Index

VOLUME VI

Diphenhydramine Derivatives: Through Manipulation toward Design

*A. F. Harms, W. Hespe, W. Th. Nauta, R. F. Rekker, H. Timmerman,
and J. de Vries*

The Design of Antiradiation Agents

Daniel L. Klayman and Edmund S. Copeland

Rational Approach to Proteinase Inhibitors

Shosuke Okamoto and Akiko Hijikata

The Design of Organ-Imaging Radiopharmaceuticals

Raymond E. Counsell and Rodney D. Ice

Design of X-Ray Contrast Media

Hans-Joachim Herms and Volker Taenzer

Agricultural Pesticides: Chemical and Physical Methods of Formulation

G. S. Hartley

Subject Index

Chapter 3. Structure-Activity-Relationships: Significance for Drug Design

Eric J. Lien

81	I. Introduction	ix
82	II. The Earlier Hypotheses Relating to the Membrane Permeability or Pharmacological Activity with Partition Coefficients	xi
84	III. Quantitative Correlations Using Multiple Regression Analysis and Substituent Constants	xiii
127	IV. Summary	
128	References	

Contents

List of Contributors

Preface

Contents of Other Volumes

ix
xi
xiii

Chapter 1. Utilization of Operational Schemes for Analog Synthesis in Drug Design

John G. Topliss and Yvonne C. Martin

I. Introduction	1
II. Operational Scheme for Aromatic Substitution	2
III. Operational Scheme for Side Chains	8
IV. Examples	11
V. Rational Follow-up to the Schemes	19
VI. Conclusion	20
References	21

Chapter 2. The Design of Enzyme Inhibitors: Transition State Analogs

R. N. Lindquist

I. Introduction	24
II. Theory of the Transition State Analog Approach	25
III. Transition State Analogs	32
IV. Natural Transition State Analog Inhibitors	68
V. Synthetic Enzymes	74
VI. Summary	75
References	76

Chapter 3. **Structure–Absorption–Distribution Relationships: Significance for Drug Design**

Eric J. Lien

I. Introduction	81
II. The Earlier Hypotheses Relating to the Membrane Permeability or Pharmacological Activity with Partition Coefficients	82
III. Quantitative Correlations Using Multiple Regression Analysis and Substituent Constants	84
IV. Summary	127
References	128

Chapter 4. **The Role of Charge-Transfer Processes in the Action of Bioactive Materials**

Peter H. Doukas

I. Introduction	133
II. Fundamentals of the Charge-Transfer Process	135
III. Charge Transfer in Biological Systems	140
IV. Summary	162
References	164

Chapter 5. **Approaches to the Rational Combination of Antimetabolites for Cancer Chemotherapy**

*Gerald B. Grindey, Richard G. Moran, and William
C. Werkheiser*

I. General Introduction	170
II. Intracellular Metabolic Interactions	172
III. Alterations in Intracellular Metabolism	218
IV. Transport or Uptake Interactions	226
V. Scheduling	231
VI. Remote Systemic Biotransformation	232
VII. Modification of Host Nutrients and Toxicity	236
VIII. Nonmetabolic Combinations	242
IX. Concluding Remarks	244
References	245

Chapter 6. **Physicochemical, Quantum Chemical, and Other Theoretical Techniques for the Understanding of the Mechanism of Action of CNS Agents: Psychoactive Drugs, Narcotics, and Narcotic Antagonists and Anesthetics**

Joyce J. Kaufman and Walter S. Koski

I. Introduction	252
II. Evaluation of Quantum Chemical Computational Methods	256
III. Psychoactive Drugs	276
IV. Narcotics and Narcotic Antagonists	301
V. Anesthetics	324
VI. Recent Developments in Sensitive Methods of Analyses for Normal Neurotransmitters and Their Metabolites	329
VII. Overall Perspective	331
References	333
 <i>Subject Index</i>	 341

a more rational approach to this problem became possible. Thus a limited group of substituents which will give good discrimination between the physicochemical parameters σ , σ^+ , and E_s relating to hydrophobic, electronic, and steric effects, respectively, can be selected (3) and an initial group of 6-12 compounds synthesized. After performing a regression analysis, and assuming a worthwhile correlation is obtained, it should be possible to determine which parameters are influencing activity and to what relative degree. Knowing this, and having available a comprehensive list of possible substituents and their respective parameters, those compounds can be selected for synthesis with the highest indicated potency values commensurate with

Chapter 1 Utilization of Operational Schemes for Analog Synthesis in Drug Design

John G. Topliss and Yvonne C. Martin

I. Introduction	1
II. Operational Scheme for Aromatic Substitution	2
III. Operational Scheme for Side Chains	8
IV. Examples	11
V. Rational Follow-up to the Schemes	19
VI. Conclusion	20
References	21

I. Introduction

A very common problem in drug design is to find the optimum substitution on a benzene ring or on the benzenoid portion of a fused ring system in an active lead compound for maximization of drug potency. Since there are many possible substituents and several different ring positions, the number of possible compounds to consider containing up to, say, two substituents is very large. Thus, it would be highly advantageous to determine at an early stage which of these compounds might really be worth synthesizing.

Historically, approaches to this problem have been rather haphazard, depending for the most part on the particular experience and intuition of the medicinal chemist involved and the relative availability of the starting materials required for synthesis. With the advent (11) and subsequent development (8) of the Hansch method for structure-activity correlations,

a more rational approach to this problem became possible. Thus, a limited group of substituents which will give good discrimination between the physicochemical parameters π , σ , and E_s° relating to hydrophobic, electronic, and steric effects, respectively, can be selected (3) and an initial group of 6–12 compounds synthesized. After performing a regression analysis, and assuming a worthwhile correlation is obtained, it should be possible to determine which parameters are influencing activity and to what relative degree. Knowing this, and having available a comprehensive list of possible substituents and their respective parameters, those compounds can be selected for synthesis with the highest indicated potency values commensurate with synthetic accessibility.

Since the regression analysis has been carried out with a minimum number of observations, the reliability of the correlation will not be high, but nevertheless the analysis will identify those compounds with the highest probability of enhanced potency based on the available data. When data on the second group of compounds become available, they can be combined with those of the first group. The correlations can thus be continuously refined as new data become available.

This procedure is suitable when the compounds are relatively easy to synthesize and a considerable time lag is encountered in obtaining activity data. However, it is less satisfactory under circumstances where synthesis is more difficult and test results are more readily forthcoming. In the latter case it would be desirable to proceed with every compound synthesized in the most probable direction toward greater potency. This maximizes the chances of finding the most potent compounds as early as possible.

Another problem in the utilization of the standard Hansch method is the reluctance on the part of some medicinal chemists to become involved with mathematics, statistical procedures, and computers. For these individuals a nonmathematical utilization of the Hansch approach might be of considerable interest.

In the context of the foregoing discussion the operational schemes (1 and 2) for aromatic substitution and side-chain problems discussed in the following sections may be considered (26). The π , σ (σ^*), and E_s° values of the substituents are listed in Table I.

II. Operational Scheme for Aromatic Substitution

For Scheme 1, which covers aromatic substitution, the assumption is made that the starting compound is the unsubstituted phenyl compound and that its biological activity has been measured. Since many systems are $+\pi$ -dependent, i.e., activity increases with increasing π values, the *p*-chloro

TABLE I
SUBSTITUENT CONSTANT VALUES

Aromatic			
Substituent	π^a	σ^b	E_s^{cc}
H	0.00	0.00	1.24
4-Cl	0.70	0.23	0.27
3-Cl	0.76	0.37	0.27
3-CF ₃	1.07	0.43	-1.16
4-NO ₂	0.24	0.78	-1.28
4-CF ₃	1.07	0.54	-1.16
4-Br	1.19	0.23	0.08
4-I	1.43	0.28	-0.16
2-Cl	0.76	0.23	0.27
4-CH ₃	0.60	-0.17	0.00
4-C(CH ₃) ₃	1.68	-0.20	-1.54
3-CH ₃	0.51	-0.07	0.00
4-OCH(CH ₃) ₂	0.76	-0.45	—
4-OCH ₂ Ph	2.09	-0.42	—
4-OPh	1.59	-0.32	—
3-Br	0.94	0.39	0.08
3-I	1.15	0.35	-0.16
3-NO ₂	0.11	0.71	-1.28
2-CH ₃	0.84	-0.17	0.00
2-OCH ₃	-0.33	-0.27	0.69
4-CN	-0.32	0.66	—
4-COCH ₃	-0.37	0.50	—
4-SO ₂ CH ₃	-1.26	0.72	—
4-CONH ₂	1.49	0.40	—
4-SO ₂ NH ₂	-1.82	0.57	—
4-F	0.15	0.06	0.78
3-N(CH ₃) ₂	0.18	-0.21	—
3-NH ₂	-1.23	-0.16	0.63
4-OCH ₃	-0.04	-0.27	0.69
4-N(CH ₃) ₂	0.18	-0.83	—
4-NH ₂	-1.23	-0.66	0.63
4-OH	-0.61	-0.37	0.69

Side chain

Substituent	π^a	σ^{*d}	E_s^{ce}
CH ₃	0.50	0.00	0.00
<i>i</i> -C ₃ H ₇	1.30	-0.19	-1.08
cyclo-C ₅ H ₉	2.14	-0.20	-1.12
cyclo-C ₆ H ₁₁	2.51	-0.15	-1.40
CH ₂ Ph	2.63	0.22	-0.69
(CH ₂) ₂ Ph	3.13	0.08	-0.69

(Continued)

TABLE I (Continued)

Side chain			
Substituent	π^a	σ^{*d}	$E_s^{e,e}$
cyclo-C ₄ H ₇	1.80 ^f	-0.20 ^f	-0.67
CH ₂ -cyclo-C ₃ H ₅	1.80 ^f	-0.13 ^f	—
tert-C ₄ H ₉	1.98 ^g	-0.30	-2.46
C ₂ H ₅	1.00	-0.10	-0.38
CHCl ₂	1.15 ^f	1.92	-2.15
CF ₃	1.07 ^f	2.76 ^f	-2.08
CH ₂ CF ₃	1.57 ^f	0.92	—
CH ₂ SCH ₃	0.77 ^f	0.44 ^f	-0.64
Ph	2.13	0.60	—
H	0.00	0.49	0.32
CH ₂ OH	-0.66 ^f	0.56	—
CH ₂ CH ₂ OH	-0.16 ^f	0.20 ^f	—
CH ₂ OCH ₃	0.02 ^f	0.64	-0.50
CH ₂ CH ₂ OCH ₃	0.52 ^f	0.23 ^f	-1.08
CH ₂ SO ₂ CH ₃	-0.76 ^f	1.32	—

^a From Fujita *et al.* (5), Iwasa *et al.* (15), Miller and Hansch (24), and Leo *et al.* (22).

^b From Hine (14) and Jaffé (16). The σ values relate to an electronic effect at the point of attachment of the phenyl group to some other moiety. It is possible that in some situations the electronic effect of a substituent may be important with respect to another position on the phenyl group. However, for the most part the arguments presented will not be materially affected.

^c From Kutter and Hansch (20).

^d From Taft (25).

^e Obtained from values taken from Taft (25) and corrected according to Hancock *et al.* (7).

^f Estimated.

^g From Hansch and Coats (10).

analog is a good first choice, particularly since the ease of synthesis, relative to other substituted phenyl compounds, is generally favorable.

For the purposes of this analysis the potency of the 4-chloro compound can be classified as greater than, equal to, or less than the activity of the parent compound. If the potency is increased, this can be attributed most probably to a $+\pi$ effect, a $+\sigma$ effect (activity increases with increasing σ values), or to a combination of $+\pi$ and $+\sigma$. In this event the 3,4-dichloro compound would be selected for synthesis next since this would result in both larger $+\pi$ and $+\sigma$ values when summed for the two substituents.